Aldi salmon recalled over fears of 'life-threatening' risk
Santa Monica Seafood voluntarily recalled its Atlantic Salmon Portions with Seafood Stuffing on Saturday due to fears they may have soy.
The affected salmon were sold in 16-ounce portions and have a use or freeze by date of June 2. The product date was printed on the white part of labels at the front of the package and under the product picture.
They were distributed at Aldi stores in Arizona, California and Nevada.
There have been no reports of consumers becoming sick from eating the stuffed salmon.
The supplier based in Rancho Dominguez, California, discovered the issue while doing a routine inspection of label proofs.
'This recall was initiated because the product contains soy, a known allergen, but the packaging does not list it as an ingredient,' stated an announcement by the US Food and Drug Administration (FDA), which is responsible for protecting public health in the nation.
'This labeling error means that individuals with a soy allergy may unknowingly consume the product.'
Customers have been advised to return the item to an Aldi store for a full refund. More Trending
Anyone with questions should call Santa Monica Seafood.
People who have a soy allergy or severe sensitivity to it 'risk a serious or life-threatening allergic reaction if they consume this product', stated the FDA.
A soy allergic reaction can cause diarrhoea, stomach cramps, vomiting, indigestion and even anaphylaxis, according to the Cleveland Clinic.
It comes just over a week after three Spar chicken products were recalled in the UK because they were found to have the bacterium Listeria monocytogene bacterium, which can cause diarrhoea and meningitis. Customers were asked to return the products, which include cooked chicken pieces, cooked chicken slices and cooked chicken fillets.
Get in touch with our news team by emailing us at webnews@metro.co.uk.
For more stories like this, check our news page.
MORE: Putin threats to 'throttle' US firms like Microsoft and Zoom in words war with Trump
MORE: At least 11 injured after gunman opens fire during boat party
MORE: Kremlin says Trump's 'absolutely crazy' jab at Putin was 'emotional overload'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
2 hours ago
- The Guardian
The Trump administration is making viruses great again
Do you enjoy getting sick from preventable diseases? Do you have a hankering to make once-declining viruses great again? If so, why not pop over to the US where the health secretary, Robert F Kennedy Jr, and his anti-vaccine cronies are making a valiant effort to overturn decades of progress in modern medicine? Let's start with measles cases, which are at their highest rate in 33 years in the US. The blame for this doesn't rest entirely with the Trump administration, of course, but officials certainly don't seem too bothered by it all. RFK Jr has downplayed the number of deaths that have occurred from measles and complained about all the headlines they're generating. Like the rest of his peers in the Trump administration, RFK Jr seems to have absolutely no idea what he is doing, and appears to be just making things up as he goes along. Indeed, the health secretary memorably told Congress in mid-May that he doesn't really think people should be taking medical advice from him. He seems to have forgotten that statement the moment the words left his mouth, however. Not even a couple of weeks later Kennedy announced that the federal Centers for Disease Control and Prevention (CDC) would stop recommending Covid-19 booster shots for healthy children and pregnant women. This was a highly unusual move, as the health secretary doesn't normally make unilateral changes to vaccine recommendations like this. While Kennedy seems to govern by vibes, actual medical experts, who rely on things like evidence and data, are deeply alarmed by the removal of the shots from officials' recommended immunization schedule. '[D]espite the change in recommendations from [health and human services], the science has not changed,' the American College of Obstetricians and Gynecologists (ACOG) said in a statement. 'It is very clear that Covid-19 infection during pregnancy can be catastrophic and lead to major disability, and it can cause devastating consequences for families.' Kennedy's decision is now facing legal opposition. In the same week that the US reached its dark measles milestone, a number of leading medical associations sued the Trump administration. 'This administration is an existential threat to vaccination in America, and those in charge are only just getting started,' said the lead counsel for the plaintiffs in a statement. Restoring trust in public health agencies and vaccines, especially among pregnant women, will take far more than a lawsuit. Two new surveys, published as a research letter in Jama Network Open, have found that only 35% to 40% of US pregnant women and parents of young children say they intend to fully vaccinate their child. To reiterate: we are now at a place where a majority of pregnant women and parents don't plan to accept all recommended kids' vaccines. 'Given the high decisional uncertainty during pregnancy about vaccinating children after birth, there may be value in intervening during pregnancy to proactively support families with childhood vaccination decisions,' the researchers wrote. Unfortunately, under this administration, that's a lot easier said than done. The president is throwing a fit over backlash to his administration's sudden U-turn on the 'Epstein Files'. On Wednesday he accused his voters of being gullible 'weaklings' who had fallen for the 'Jeffrey Epstein Hoax' which, according to him, is a 'SCAM' cooked up by the 'Lunatic Left' to discredit him. (If it's all a hoax, why is Ghislaine Maxwell in prison, eh?) Then, on Thursday, Status News reported that Trump had called the editor-in-chief of The Wall Street Journal to try to block its story on Trump's relationship with the disgraced financier. No matter how many insults he flings around or threats he makes, Trump can't bury the bigger Epstein story. Instead people are more invested in finding out who Epstein's associates were than ever before and polls show most Americans believe the government is concealing information. Trump may want to look up the Barbra Streisand effect. The 25-year-old's father allegedly felt threatened because she helped support him financially. The poet and performance artist died of ovarian cancer. 'Whenever I leave this world, whether it's sixty years from now, I wouldn't want anyone to say I lost some battle,' Gibson once wrote. 'I'll be a winner that day.' Gibson was a winner this week, but the world has lost a force for good. Back in 2014, the Oscar-winning actor had surgery to remove 30 uterine fibroids– non-cancerous tumors that can cause severe pain and heavy menstrual bleeding. Black women are three times more likely to develop fibroids than white women. July is Fibroid Awareness Month and, on Tuesday, the actor helped introduce a US uterine health legislative package aimed at introducing better prevention and screening protocols and less invasive treatments. 'I hope to seek answers for the far too many women dealing with uterine fibroids,' Nyong'o said. 'We must reject the normalization of female pain.' 'We are deeply concerned about women's access to health care, especially maternal health care, in ICE detention,' the caucus wrote in a letter. They reference the case of a woman who delivered a stillborn baby after being detained in immigration custody and allegedly having medical care delayed. Sign up to The Week in Patriarchy Get Arwa Mahdawi's weekly recap of the most important stories on feminism and sexism and those fighting for equality after newsletter promotion The Tufts University doctoral student Rümeysa Öztürk writes about her 45 days in a south Louisiana processing facility. Someone needs to give that man contraceptive advice, but OK. In her new memoir, Southern says Tate strangled her in a hotel bed in 2018 and assaulted her. 'No one wants to be a victim, especially not when you come from my political background,' Southern wrote. 'I know exactly what's coming. I'll be crucified online. I'm not looking for sympathy, and I don't expect a victim trophy from any side. I'm publishing this simply because it's the truth and far too few people are telling the truth these days.' Tate, who has been accused of rape and bodily harm by multiple women, responded by accusing Southern of drumming up publicity for her memoir. Husam Masrouf, a poet from Gaza, has a surreal and haunting piece in Flaming Hydra about the lengths some starving Palestinian women are going to try to obtain nutritional supplements. You think the US is turning into a police state? I'm afraid things are not any better in the UK, where armed police may threaten to arrest you simply for peacefully holding a Palestinian flag. We live in an upside down world where accused war criminals like Benjamin Netanyahu are wined and dined by politicians, while protesting against the murder of more than 17,000 children is treated as some sort of crime. Turns out your canine companion may secretly be judging you for your reality TV habit. A new study has found that dogs engage meaningfully with the TV and have certain viewing preferences. I reckon my little chihuahua is a big fan of Game of Bones and RuPaw's Drag Race. Arwa Mahdawi is a Guardian columnist
Daily Mail
12 hours ago
- Daily Mail
I tested natural deodorant after FDA recalled 67,000 cases of popular brands - here's why I'll never go back
With the FDA recalling 67,000 cases of popular deodorant brands, one journalist made the switch to natural deodorant and was shocked by the results. Sophie Bates, a writer for The Sun, tried the natural product from Wild, a company that launched in 2020 with a focus on eco and skin-friendly products. Bates tested the deodorant daily for a month, putting it to the test through the office, gym and overnight. She went in with concerns of irritation and effectiveness, but found she was 'pleasantly surprised' by the product. 'For the first few days [I] didn't feel as fresh as I usually would with a traditional deodorant, but after that, I didn't notice much difference at all,' she said. 'I found myself free from body odor for the majority of the day, but I did sweat more than I usually do at first.' Bates said that while the natural deodorant took 'some getting used to,' she found that any odor neutralized following a couple of days of use. 'Everything about Wild is natural, from the recycled packaging to the chemical-free formula, but without compromising on quality,' she added. 'Once you get over the initial transition period, Wild's deodorant effectively keeps odor at bay, and I noticed long-lasting results without needing to top up.' Bates said the deodorant, while a little messy and more expensive, was overall a great natural option. Wild is available from $16 for cases and refills, $7.50 for refills and $11 for cases only, with a choice of scents and packaging options. The company's refillable options for natural deodorant is in an effort to reduce single-use plastics, and it claims that each refill saves 30 grams of plastic from reaching landfill sites. Bates testing of the product comes as the FDA announced a recall of 67,000 cases of the popular Power Stick deodorant brand. The Pennsylvania-based manufacturer, A.P Duauville, LLC, initiated the voluntary recall of 67,214 cases in total on July 10. The recall included more than 20,000 cases of the brand's 'power fresh'-scented Power Stick for Her Roll-On Antiperspirant Deodorant. It also covered more than 22,400 cases of 'spring fresh'-scented Power Stick Invisible Protection Roll-On Antiperspirant Deodorant, and more than 23,400 cases of the brand's Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant. The Pennsylvania-based manufacturer, A.P Duauville, LLC, initiated the voluntary recall of 67,214 cases in total on July 10 All recalled items were packaged in a 1.8 ounce size. The recall was issued due to reported 'cGMP deviations,' which indicates a procedure and standards issue for product manufacturing, according to the Current Good Manufacturing Practices. Customers were able to purchase the recalled products at Walmart, Dollar Tree and Amazon.
The Independent
19 hours ago
- The Independent
Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths
Drugmaker Sarepta Therapeutics said late Friday it won't comply with a request from the Food and Drug Administration to halt all shipments of its gene therapy following the death of a third patient receiving one of its treatments for muscular dystrophy. The highly unusual move is a latest in a string of events that have hammered the company's stock for weeks and recently forced it to lay off 500 employees. The company's decision not to comply with the FDA also places future availability of its leading therapy, called Elevidys, in doubt. The FDA said in a statement Friday night that officials met with Sarepta and requested it suspend all sales but 'the company refused to do so.' The agency has the authority to pull drugs from the market, but the cumbersome regulatory process can take months or even years. Instead, the agency usually makes an informal request and companies almost always comply. 'We believe in access to drugs for unmet medical needs but are not afraid to take immediate action when a serious safety signal emerges,' FDA Commissioner Marty Makary said in a statement. Elevidys is the first gene therapy approved in the U.S. for Duchenne's muscular dystrophy, the fatal muscle-wasting disease that affects males, though it has faced scrutiny since its clearance in 2023. The one-time treatment received accelerated approval against the recommendations of some FDA scientists who doubted its effectiveness. The FDA granted full approval last year and expanded the therapy's use to patients 4 years and older, including those who can no longer walk. Previously, it was only available for younger patients who were still walking. Sarepta said Friday that its scientific review showed 'no new or changed safety signals' for younger patients with Duchenne's who have earlier stages of the disease. The company said it plans to keep the drug available for those patients. 'We look forward to continued discussions and sharing of information with FDA,' the company said in a statement. Sarepta halted shipments last month of the therapy for older boys with Duchenne's, which gradually destroys muscle and skeletal strength, resulting in early death. The move followed the deaths of two teenage boys taking the therapy. The company also confirmed a third death Friday: a 51-year-old patient who was taking an experimental gene therapy in a trial for a different form of muscular dystrophy. Sarepta said it reported the death to the FDA on June 20. The FDA said Friday it placed that trial on hold. Sarepta noted that the gene therapy involved in the incident uses 'a different dose and is manufactured using a different process,' than Elevidys. All three patient deaths were linked to liver injury, a side effect noted in Sarepta's prescribing information. Earlier this week Sarepta announced it would add a bold warning to drug and lay off a third of its employees. The company did not mention the third patient death in its news release or conference call announcing those changes, sparking pointed criticism from Wall Street analysts. Company shares fell more than 35% Friday to close at $14.07. Cambridge, Massachusetts-based Sarepta has received FDA approval for three other Duchenne's drugs since 2016, none of which have been confirmed to work. The company has long been criticized for failing to complete several studies needed to secure full FDA approval of its drugs. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
